Wave Life Sciences has seen its share price fall 64.0% year to date, yet the valuation checks suggest the stock still screens as expensive rather than a clear bargain. Wave Life Sciences is down 64.0% ...

Wave Life Sciences (WVE) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

Life sciences companies continue to operate in an environment supported by growing investment in biomedical research, ...

Is Exact Sciences (NASDAQ: EXAS) about to go on a sustained run? The medical diagnostics specialist has lagged the market over the trailing-12-month period, but the stock is rebounding. In the past ...

Caris Life Sciences proprietary WES/WTS/WGS technology and massive data advantage underpin its leadership in oncology ...

In the latest close session, Gilead Sciences (GILD) was down 3.72% at $129.83. The stock's performance was behind the S&P 500 ...

Exact Sciences Corp (NASDAQ:EXAS) shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the details from the report. The Details: Exact ...

On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping ...

SHANGHAI, CHINA - NOVEMBER 07: People visit the Gilead Sciences Inc. booth during the 6th China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) on November ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...